[redacted]

# Active substances set

**Search phrase:** imlunestrant

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Malignant breast cancer

| | | |
|---|---|---|
| **Imlunestrant** | Imlunestrant is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen. | NO REIMBURSEMENT<br>ESMO |